105 related articles for article (PubMed ID: 28580722)
1. Response to "Quantitative analysis of hepatocellular adenoma and focal nodular hyperplasia in the hepatobiliary phase: External validation of llcer method using gadobenate dimeglumine as contrast agent".
Roux M; Pigneur F; Luciani A
J Magn Reson Imaging; 2018 Mar; 47(3):862-863. PubMed ID: 28580722
[No Abstract] [Full Text] [Related]
2. Quantitative analysis Of hepatocellular adenoma and focal nodular hyperplasia in the hepatobiliary phase: External validation of LLCER method using gadobenate dimeglumine as contrast agent.
Thomeer MG; Gest B; van Beek H; De Vries M; Dwarkasing R; Klompenhouwer AJ; De Man RA; IJzermans JN; Braun L
J Magn Reson Imaging; 2018 Mar; 47(3):860-861. PubMed ID: 28589549
[No Abstract] [Full Text] [Related]
3. Differentiation of focal nodular hyperplasia from hepatocellular adenoma: Role of the quantitative analysis of gadobenate dimeglumine-enhanced hepatobiliary phase MRI.
Roux M; Pigneur F; Calderaro J; Baranes L; Chiaradia M; Tselikas L; Decaens T; Costentin C; Laurent A; Azoulay D; Mallat A; Zafrani ES; Rahmouni A; Luciani A
J Magn Reson Imaging; 2015 Nov; 42(5):1249-58. PubMed ID: 25851028
[TBL] [Abstract][Full Text] [Related]
4. Quantitative correlation between uptake of Gd-BOPTA on hepatobiliary phase and tumor molecular features in patients with benign hepatocellular lesions.
Reizine E; Amaddeo G; Pigneur F; Baranes L; Legou F; Mulé S; Zegai B; Roche V; Laurent A; Rahmouni A; Calderaro J; Luciani A
Eur Radiol; 2018 Oct; 28(10):4243-4253. PubMed ID: 29721686
[TBL] [Abstract][Full Text] [Related]
5. Quantitative information from gadobenate dimeglumine-enhanced MRI can predict proliferative subtype of solitary hepatocellular carcinoma: a multicenter retrospective study.
Ding F; Huang M; Ren P; Zhang J; Lin Z; Sun Y; Liang C; Zhao X
Eur Radiol; 2024 Apr; 34(4):2445-2456. PubMed ID: 37691080
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis of focal nodular hyperplasia with MRI: multicenter retrospective study comparing gadobenate dimeglumine to gadoxetate disodium.
Gupta RT; Iseman CM; Leyendecker JR; Shyknevsky I; Merkle EM; Taouli B
AJR Am J Roentgenol; 2012 Jul; 199(1):35-43. PubMed ID: 22733891
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient.
Kim HJ; Kim BS; Kim MJ; Kim SH; de Campos RO; Hernandes M; Semelka RC
J Magn Reson Imaging; 2013 Apr; 37(4):903-8. PubMed ID: 23065959
[TBL] [Abstract][Full Text] [Related]
8. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study.
Grazioli L; Morana G; Kirchin MA; Schneider G
Radiology; 2005 Jul; 236(1):166-77. PubMed ID: 15955857
[TBL] [Abstract][Full Text] [Related]
9. Reply to "Intrapatient Comparison of the Hepatobiliary Phase of Gd-BOPTA and Gd-EOB-DTPA in the Differentiation of Hepatocellular Adenoma From Focal Nodular Hyperplasia".
Reizine E; Luciani A
J Magn Reson Imaging; 2020 Oct; 52(4):1279-1280. PubMed ID: 32022384
[TBL] [Abstract][Full Text] [Related]
10. The value of gadobenate dimeglumine-enhanced hepatobiliary-phase MR imaging for the differentiation of scirrhous hepatocellular carcinoma and cholangiocarcinoma with or without hepatocellular carcinoma.
Jeon TY; Kim SH; Lee WJ; Lim HK
Abdom Imaging; 2010 Jun; 35(3):337-45. PubMed ID: 19350315
[TBL] [Abstract][Full Text] [Related]
11. Focal nodular hyperplasia: intraindividual comparison of dynamic gadobenate dimeglumine- and ferucarbotran-enhanced magnetic resonance imaging.
Marin D; Iannaccone R; Laghi A; Catalano C; Murakami T; Hori M; Kim T; Passariello R
J Magn Reson Imaging; 2007 Apr; 25(4):775-82. PubMed ID: 17348002
[TBL] [Abstract][Full Text] [Related]
12. Arterial enhancing-only nodules less than 2 cm in diameter in patients with liver cirrhosis: predictors of hepatocellular carcinoma diagnosis on gadobenate dimeglumine-enhanced MR imaging.
Quaia E; Pizzolato R; De Paoli L; Angileri R; Ukmar M; Cova MA
J Magn Reson Imaging; 2013 Apr; 37(4):892-902. PubMed ID: 23097278
[TBL] [Abstract][Full Text] [Related]
13. MR-imaging features of hepatocellular carcinoma capsule appearance in cirrhotic liver: comparison of gadoxetic acid and gadobenate dimeglumine.
Dioguardi Burgio M; Picone D; Cabibbo G; Midiri M; Lagalla R; Brancatelli G
Abdom Radiol (NY); 2016 Aug; 41(8):1546-54. PubMed ID: 27052455
[TBL] [Abstract][Full Text] [Related]
14. The MR imaging diagnosis of liver diseases using gadoxetic acid: emphasis on hepatobiliary phase.
Jeong WK; Kim YK; Song KD; Choi D; Lim HK
Clin Mol Hepatol; 2013 Dec; 19(4):360-6. PubMed ID: 24459639
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory hepatic adenomas: Characterization with hepatobiliary MRI contrast agents.
Glockner JF; Lee CU; Mounajjed T
Magn Reson Imaging; 2018 Apr; 47():103-110. PubMed ID: 29221964
[TBL] [Abstract][Full Text] [Related]
16. MRI of focal nodular hyperplasia (FNH) with gadobenate dimeglumine (Gd-BOPTA) and SPIO (ferumoxides): an intra-individual comparison.
Fröhlich JM
J Magn Reson Imaging; 2004 Mar; 19(3):375-6; author reply 376. PubMed ID: 14994308
[No Abstract] [Full Text] [Related]
17. Gadobenate dimeglumine-enhanced liver magnetic resonance imaging: value of hepatobiliary phase for the detection of focal liver lesions.
Fu GL; Du Y; Zee CS; Yang HF; Li Y; Duan RG; Zeng NL; Xiao DM
J Comput Assist Tomogr; 2012; 36(1):14-9. PubMed ID: 22261765
[TBL] [Abstract][Full Text] [Related]
18. MRI features of inflammatory hepatocellular adenomas on hepatocyte phase imaging with liver-specific contrast agents.
Thomeer MG; Willemssen FE; Biermann KK; El Addouli H; de Man RA; Ijzermans JN; Dwarkasing RS
J Magn Reson Imaging; 2014 May; 39(5):1259-64. PubMed ID: 23897798
[TBL] [Abstract][Full Text] [Related]
19. Hepatocyte-specific magnetic resonance imaging contrast agents.
Fidler J; Hough D
Hepatology; 2011 Feb; 53(2):678-82. PubMed ID: 21274888
[No Abstract] [Full Text] [Related]
20. Evaluation of Hepatocellular Carcinoma Tumor Response After Transcatheter Arterial Chemoembolization Using Gadobenate Dimeglumine-Enhanced Liver Magnetic Resonance.
Chu LC; Pozzessere C; Corona-Villalobos CP; Castaños S; Rastegar N; Halappa V; Bonekamp S; Emurano E; Kamel IR
J Comput Assist Tomogr; 2016; 40(6):856-862. PubMed ID: 27680411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
